OnCo
trialsTrialMixed

DUO-O / ENGOT-ov46

Adding immunotherapy and olaparib to bevacizumab slowed progression but has not improved survival, and the regimen is not approved.

PFS HR 0.63 in the non-tBRCAm intent-to-treat population for the durvalumab + olaparib arm (ASCO 2023). Interim OS HR 0.95 (39% maturity; Annals of Oncology 2025) showed no survival signal. Immunotherapy has otherwise failed repeatedly in first-line ovarian cancer (IMagyn050, JAVELIN Ovarian 100).

Setting
Newly diagnosed non-BRCA-mutated advanced ovarian cancer: chemotherapy + bevacizumab + durvalumab, then durvalumab + bevacizumab ± olaparib maintenance, vs standard
Phase
Phase 3
Sponsor
AstraZeneca
Registry
NCT03737643
Headline result
PFS HR 0.63; interim OS HR 0.95.
Reported
2023
Enrolled
1130

Outcomes

1top
In plain words
What these results mean for people, not percentages
1,130 people took part
Progression-free survival (non-tBRCAm ITT)primarysurrogate endpoint
  • The treated group had about 37 percent lower chance of the event at any given time (hazard ratio 0.63).
  • The absolute difference, how many more people out of 100 were helped, is not reported here.
  • This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
  • These results apply to the people the trial enrolled: Newly diagnosed non-BRCA-mutated advanced ovarian cancer: chemotherapy + bevacizumab + durvalumab, then durvalumab + bevacizumab ± olaparib maintenance, vs standard. People in a different situation may not see the same effect.
  • The trial selected people by a biomarker (BRCA); the result should not be assumed for people whose cancer does not have it.

Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

1,130 participants enrolled.

Progression-free survival (non-tBRCAm ITT)primary
HR 0.63 (0.52–0.76)

Numbers not yet public.

Source
EndpointArmnValueHR (95% CI)pSource
Progression-free survival (non-tBRCAm ITT)primaryDurvalumab + olaparib + bevacizumab——0.63 (0.52–0.76)—link
Bevacizumab + placebo——

Connected

7top

Pages like this

not linked directly; found by shared links

cancers

1
Ovarian cancer

targets

2
PARPPD-L1

drugs

3
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
ApprovedMonoclonal antibody (anti-PD-L1)
Durvalumab · Imfinzi
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza

pairings

1
Caution: checkpoint inhibitors in first-line ovarian cancer